Publications

Below you will find our key publications. Check PubMed for more publications by Sabine Linn.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC.
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose, platinum-based, chemotherapy in HER2-negative breast cancer patients.
Ann Oncol 2010 [Epub ahead of print].

Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, and Linn SC.
Ligands of EGFR and the insulin-like growth factor family as serum biomarkers for response to EGFR-inhibitors in patients with advanced NSCLC.
J Thorac Onc, 5:1939-1948, 2010.

Kok M, Holm C, Hauptmann M, Michalides R, Stal O, Linn S, Landberg G.
Phosphorylation of the estrogen receptor alpha at serine 118 predicts tamoxifen response in breast cancer: results from a randomized controlled trial.
J Natl Cancer Inst, 102:208, 2010.

Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC.
Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.
Ann Oncol, 2009, [Epub ahead of print].

Holm C, Kok M, Michalides R, Fles R, Koornstra RHT, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stål O, Landberg G, Linn SC.
Phosphorylation of the Oestrogen Receptor a at Serine 305 and Prediction of Tamoxifen Resistance in Breast Cancer.
J Pathol, 217: 372-379, 2009.

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van ’t Veer LJ, van Dam FSAM, Karsenberg K, Douma KFL, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJT, Brink G, Floore AN, Glas AM, Roumen RMH, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Lancet Oncol, 8: 1079-1087, 2007.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Ajouaou A, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.
A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer.
Cancer Cell, 12: 395-402, 2007.

Meuwissen R, Linn SC, Linnoila I, Zevenhoven J, Mooi WJ, Berns A.
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.
Cancer Cell, 4: 181-189, 2003.

Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M.
Molecular characterisation of soft tissue tumours: a gene expression study.
Lancet, 359: 1301-1307, 2002.

Linn SC, van Ark-Otte J, Pinedo HM, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G.
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.
Int J Cancer, 71: 787-795, 1997.